INTRODUCTION
B cell development, activation, and tolerance are interconnected processes controlled by signals delivered by the B cell receptor (BCR) (Healy and Goodnow, 1998; Rajewsky, 1996; Reth and Wienands, 1997) . Paradoxically, the same BCR can either signal immunogenically, stimulating the proliferation and differentiation of B cells specific for foreign antigens, or signal tolerogenically to eliminate or silence cells that bind to self-antigens. Although divergent hypotheses exist as to how precisely BCR signaling is triggered by antigen and how this signaling is quantitatively and differentially altered in tolerized B cells (Healy et al., 1997; Vilen et al., 2002) , the developmental timing when B cells encounter antigens may determine the final outcomes (Cancro, 2004; Chung et al., 2003) . In particular, evidence indicate that triggering of the antigen receptors on bone-marrow (BM) immature and peripheral transitional (T1 or T2) B cells leads to B cell tolerance in the absence of T cell help (Allman et al., 1992; Carsetti et al., 1995; Fulcher and Basten, 1994) . These findings thus support the idea that the immature stages of B cell development may represent a time window during which B cell tolerance is established. After these stages, binding of antigens to the BCR on mature B cells results in B cell activation.
The BCR complex is composed of antigen-binding immunoglobulin Ig molecules and noncovalently associated signal-transduction molecules, Ig-a-and Ig-b-containing cytoplasmic domain immunoreceptor tyrosine-based activation motifs (ITAMs) (Cambier, 1995b; Campbell, 1999; Reth, 1989 Reth, , 1992 . Crosslinking of the BCR results in tyrosine phosphorylation of the ITAMs by Src-family tyrosine kinase Lyn followed by recruitment and activation of Syk tyrosine kinase (Cambier, 1995a; Reth and Wienands, 1997) . Recruitment and activation of Syk by the phosphorylated BCR is a key event in the assembly of the BCR signalosome composed of the adaptor protein BLNK (B cell linker protein) and downstream signaling components phospholipase C-g2 (PLC-g2), Bruton's tyrosine kinase (Btk), and Rho-family GTP-GDP exchange factor Vav (Kurosaki, 2002; Pierce, 2002) . These components coordinately induce Ca 2+ influx and activate nuclear-transcription factors including NF-AT, AP-1, and NF-kB that are essential for B cell development and activation (Campbell, 1999; Kurosaki, 2000) .
Casitas B lineage lymphoma (Cbl) proteins were recently identified as E3 ubiquitin ligase (Joazeiro et al., 1999) . They interact with E2-ubiquitin-conjugating enzyme (Ubc) through their RING finger (RF) domain and regulate the signaling of a broad range of receptors by promoting ubiquitination of the components involved in this receptor signaling (Duan et al., 2004; Liu and Gu, 2002; Thien and Langdon, 2005) . In mammals, the Cbl family of proteins has three members, Cbl, Cbl-b, and Cbl-3, among which Cbl and Cbl-b are expressed in hematopoietic cells (Duan et al., 2004) . Recent genetic studies from our and several other laboratories have revealed a critical role of Cbl proteins in T cell development and activation (Bachmaier et al., 2000; Chiang et al., 2000; Murphy et al., 1998; Naramura et al., 1998 Naramura et al., , 2002 . The role of Cbl in B cell development and function requires further investigation. The involvement of Cbl proteins in BCR signaling has been reported in several papers, in which Cbl and Cbl-b were shown to regulate PLC-g2 activation and Ca 2+ response (Sohn et al., 2003; Yasuda et al., 2000 Yasuda et al., , 2002 . Cbl proteins associate with Syk and BLNK upon BCR stimulation, suggesting that they are part of the BCR signalosome. Cbl-b deficiency leads to an enhanced tyrosine phosphorylation of Syk and Ca 2+ response in mouse B cells, despite normal BCR-induced proliferation of Cblb À/À B cells (Sohn et al., 2003) . However, the precise signaling and physiological function of Cbl proteins in B cell biology has not yet been fully addressed, to some extent as a result of functional redundancy between Cbl and Cbl-b. In order to understand the biochemical and physiological functions of Cbl proteins in B cells, we have generated a mouse model in which Cbl and Cbl-b are simultaneously inactivated in B lineage cells. Our study revealed that these mice manifested systemic lupus erythematosus (SLE)-like disease. The mutation substantially increased the rate of B cell maturation and impaired B cell anergy. These results thus indicate that Cbl proteins control a checkpoint of B cell tolerance, possibly by extending the duration of B cell maturation, providing sufficient time for the induction of B cell tolerance.
RESULTS

Generation of B Cell-Specific Cbl and Cbl-b Double-Deficient Mice
Our previous data demonstrate that inactivation of the germline Cbl or Cblb gene alone results in a negligible impact on the development and function of B cells; however, the simultaneous ablation of both Cbl and Cblb genes in germline leads to embryonic lethality (Naramura et al., 2002) BAFF (B cell activation factor of the tumor necrosis factor family) signaling plays a critical role in B cell survival, and enhanced BAFF signaling has been linked to B cellmediated autoimmune diseases (Lesley et al., 2004; Thien et al., 2004 Impaired B Cell Anergy to Self-Antigen in Cbl
Whereas B cell tolerance can be achieved through different mechanisms such as clonal deletion, BCR editing, and anergy of autoreactive B cells (Chen et al., 1995; Goodnow et al., 1988 Goodnow et al., , 1995 Nemazee and Buerki, 1989) , induction of anergy to self-antigen is a final safeguard to prevent autoreactivity (Rajewsky, 1996 Figures 4A and 4B ). Additionally, upon anti-IgM stimulation, the mutant B cells efficiently upregulated CD86 and MHC II and elicited Ca 2+ influx albeit at an amount slightly lower than that in WT cells ( Figure 4C ). On the contrary, the WT Ig HEL B cells from Ig HEL sHEL double-transgenic mice exhibited typical Figure 4C ). Based on these data, we conclude that B cell anergy is at least one of the major reasons that contribute to the manifestation of the SLE-like autoimmune disease in these mice.
Differential Alterations of BCR-Proximal Signaling in Cbl
The strength of BCR-proximal signaling plays a critical role in peripheral B cell tolerance and activation (Monroe, 2004; Rajewsky, 1996) . It may also dictate the development and differentiation of immature B cells into follicular, B1, and MZ B cells: it has been shown that strong BCR signaling facilitates the development of MZ and B1 B cells whereas weak BCR signaling favors the differentiation of follicular B cells (Casola et al., 2004) . The Cbl
mutation altered the ratios of follicular B cells to B1 and MZ B cells ( Figure 1C ), so we decided to assess whether BCR-proximal signaling was enhanced in Cbl À/À Cblb À/À B cells after anti-IgM stimulation. We found that stimulation of Cbl À/À Cblb À/À B cells elicited markedly enhanced and prolonged tyrosine phosphorylation of total cellular proteins as compared to that of WT B cells ( Figure 5A ). In particular, the mutant B cells exhibited substantially protracted higher amounts of tyrosine phosphorylation of Ig-a, Syk, PLC-g2, and Vav, as well as Erk MAP kinase activities, than did the control cells ( Figure 5B ). Additionally, a prolonged and elevated amount of Ca 2+ mobilization was also found in Cbl
to WT cells ( Figure 5C) . Surprisingly, tyrosine phosphorylation of BLNK was dramatically decreased in the mutant B cells as compared to that in WT B cells ( Figure 5B ), indicating that the Cbl À/À Cblb À/À mutation exerted a differential effect on BCR-proximal signaling pathways. A strong phosphorylated band of approximate 70-75 kDa was reproducibly coimmunoprecipitated with BLNK, although the identity of this protein remained unclear ( Figure 5B ). Taken together, we conclude that Cbl proteins differentially control both the strength and duration of multiple BCR-proximal signaling pathways. Additionally, since most BCR-proximal signaling pathways are enhanced whereas BLNK phosphorylation is attenuated in Cbl (Fang and Liu, 2001; Naramura et al., 2002; Rao et al., 2002b) . The BCR delivers signals in a manner similar to the TCR, so we investigated whether the Cbl (Figure 6A ). In the absence of crosslinking, the mutant B cells expressed a slightly higher amount of cell-surface IgM than did the WT cells. Although BCR crosslinking for 5 min already resulted in a substantial loss of cell-surface IgM on the WT B cells, the same treatment induced little change with respect to the amount of cell-surface IgM on the mutant B cells for at least 20 min, indicating that Cbl proteins indeed play a critical role in BCR downmodulation. Cbl proteins form complexes with BCR-downstream signaling components, including Ig-a, Syk, PLC-g2, BLNK, PI-3 kinase (p85), and Vav. To explore whether Cbl protein-mediated ubiquitination was involved in BCR downmodulation and BCR signaling, we examined ubiquitination of these signaling components in WT and Cbl
Ig-a and Syk were heavily ubiquitinated in WT but not Cbl Figure 6B ). By contrast, we could not detect any meaningful ubiquitination of PLC-g2, BLNK, PI-3 kinase (p85), and Vav in either WT or Cbl À/À Cblb À/À B cells (data not shown). Interestingly, despite their ubiquitinations, the amounts of Ig-a and Syk in WT B cells did not seem to be affected even at 60 min after the stimulation ( Figure 6B and data not shown), suggesting that Cbl proteins might regulate the signaling of these molecules through a nondegradation mechanism.
Taken together, our results indicate that Cbl proteins selectively promote ubiquitination of the BCR-downstream signaling components including Ig-a and Syk during BCR activation. Ig-a is constitutively associated with membrane IgM and its ubiquitination state is closely correlated with the BCR downmodulation, so it is therefore likely that Cbl proteins downmodulate the activated BCR, hence the BCR signaling by promoting Ig-a ubiquitination.
DISCUSSION
In this study, we show that the simultaneous ablation of E3 ubiquitin ligases Cbl and Cbl-b in B cells results in manifestation of SLE-like autoimmune disease, as evidenced by high production of serum autoantibodies against dsDNA and ANA, as well as pathological alterations in kidney and other major organs. Cbl À/À Cblb À/À B cells were not generally hyperresponsive to antigen stimulation in terms of antibody production and proliferation. However, BCR anergy to soluble protein antigen (sHEL) was impaired. Because in this mouse model the Cbl and Cbl-b are simultaneously inactivated only in B cells, we conclude that Cbl proteins control B cell-intrinsic checkpoint of tolerance induction.
B cell-mediated autoimmunity is frequently linked to the hyperactivation of B cells. In this regard, mice deficient in tyrosine kinase Lyn, tyrosine phosphatase SHP-1, or membrane receptor CD22 exhibit B cell hyperresponsiveness upon BCR stimulation and manifest systemic autoimmune diseases Hibbs et al., 1995; O'Keefe et al., 1996) . In addition to this mechanism, mutations that influence B cell apoptosis and survival may also affect immune tolerance, because the germline deletion of protein kinase C-d (PKC-d) or overproduction of BAFF in mice, both of which promote the survival of B cells, cause severe autoimmune diseases (Lesley et al., 2004; Saijo et al., 2003; Thien et al., 2004) . In contrast to these two mechanisms, we found that Cbl À/À Cblb À/À B cells were not hyperactive to antigen stimulation either in vitro or in vivo. They were not resistant to BCR-induced apoptosis, nor did they exhibit any enhancement in BAFF signaling. These findings therefore suggest that Cbl proteins control B cell tolerance through a different mechanism. It is generally believed that B cell tolerance may occur at immature B cell stage. In contrast to mature B cells that are activated when encountering an antigen, immature B cells usually become tolerized upon BCR triggering (Allman et al., 2001; Carsetti et al., 1995; Loder et al., 1999; Monroe, 2004; Rajewsky, 1996) . Under physiological condition, immature B cells may take 3-4 days to become immune-competent mature B cells (Allman et al., 1993; Rolink et al., 1998) . This period of B cell maturation naturally constitutes a time window when autoreactive B cells can be checked by various tolerance mechanisms such as clonal deletion, BCR editing, and anergy (Chen et al., 1995; Goodnow et al., 1995; Nemazee and Buerki, 1989) . Our preliminary data suggest that the Cbl
Cblb À/À mutation may expedite B cell maturation (data not shown). We therefore propose that this alteration could dramatically shorten the susceptible period of immune tolerance against autoreactive B cells, consequently breaking down the immune tolerance. This hypothetic model of B cell tolerance is also supported by a recent observation that administration of female hormone prolactin may concomitantly facilitate B cell maturation and development of SLE-like disease in anti-DNA antibody transgenic mice (Peeva et al., 2003 (Joazeiro et al., 1999) . Cbl and Cbl-b directly or indirectly form complexes with the Ig-a, Syk, PLC-g2, PI-3 kinase (p85), Vav, and BLNK (Bachmaier et al., 2000; Fang and Liu, 2001; Rao et al., 2002a; Sohn et al., 2003 ; and data not shown). However, we noted that in B cells, the Cbl
BCR-induced Ig-a and Syk ubiquitination but did not affect the ubiquitination states of PI-3 kinase, PLC-g2, Vav, and BLNK, despite the fact that tyrosine phosphorylation of these molecules was markedly altered. Ig-a and Syk function at the top of the BCR-signaling cascade, so our results thus support the idea that Cbl proteins may negatively regulate BCR-signaling cascade at the top of BCR-induced tyrosine phosphorylation cascade by promoting Ig-a and Syk ubiquitination. We could not detect any meaningful degradation of Ig-a and Syk even after 1 hr of BCR stimulation, so we believe that the ubiquitination of Ig-a and Syk by Cbl proteins might not direct them for degradation, but rather alter their transportation and/or association with other molecules during BCR signaling. A similar observation that PI-3 kinase (p85) is ubiquitinated but not degraded by Cbl-b has been reported in T cells (Fang and Liu, 2001 ). This conclusion of course cannot exclude the possibility that only a small fraction of Ig-a and Syk are ubiquitinated by Cbl proteins so that the degradation of these molecules is below the detectable level in our assay system. It should be mentioned that T cells in our Cbl
mice were deficient in Cbl-b. Because our Cblb À/À mice are susceptible to autoimmune diseases (Chiang et al., 2000) , it is possible that in Cbl 
EXPERIMENTAL PROCEDURES
Mice Cbl-floxed, Cblb-deficient, and Cd19-Cre transgenic mice were described previously (Naramura et al., 2002) . To generate Cbl
mice, Cbl-floxed mice were crossed to Cblb À/À mice and then to
Cd19-Cre transgenic mice kindly provided by A. Tarakhovsky and K. Rajewsky (Rickert et al., 1997) . Mice used in this study were of a mixed C57BL/6 and 129 background. Ig HEL and sHEL transgenic mice were originally generated by Goodnow et al. (1988) and were kindly provided by A. Tarakhovsky. All mice used in this study were maintained and used at The Twinbrook II Facility of NIAID and the Columbia University Hammer Health Science Center mouse facility under specific pathogen-free conditions according to institutional guidelines and animal study proposals approved by the institutional animal care and use committees.
Antibodies and Reagents CD5, CD21, CD23, CD24 (HSA), B220, IgM, IgD, CD69, CD86, I-A b , and AA4.1 antibodies were from BD PharMingen. The purified and biotinylated goat anti-mouse IgM F(ab') 2 antibody used for BCR crosslinking was from Jackson Immunoresearch Laboratory. Ig-a antibody was from S.K. Pierce. Anti-BLNK was obtained from A. Chan and D. Kitamura. Anti-Syk, PLC-g2, Vav, ubiquitin, phospho-ERK, and ERK1/2 were from Santa Cruz Biotechnology, Inc. Anti-phosphotyrosine (4G10) was from Upstate. BAFF was from Apotech Biochemicals. Anti-CD40 and IL-4 were from BD PharMingen.
T-Dependent and T-Independent Antibody Responses and ELISA 6-to 10-week-old mice were immunized i.p. with 50 mg of NP-KLH for TD immune response, NP-Ficoll for type I TI immune response, or NP-LPS for type II TI immune response. The antigens were precipitated in 100 ml of Imject-Alum adjuvant (Pierce) . Immunized mice were bled from the tail vein on day 7 and 14 after primary immunization. The titers of NP-specific antibodies of different Ig isotypes were determined by ELISA as described previously (Chiang et al., 2000) .
In Vitro B Cell Proliferation and Apoptosis Assays B cells were purified with MACS column according to a B cell enrichment protocol (Miltanyi Biotek) and were more than 95% pure based on cell-surface CD19 staining. FACS purification of T1 and T2 (AA4.1 hi HSA hi ) and follicular (AA4.1 lo HSA lo CD21 hi CD23 hi ) B cells was performed after staining cells with anti-AA4.1, HSA, CD23, and CD21. Purified B cells (1 3 10 5 cells/well) were stimulated with 10 mg/ml anti-IgM F(ab') 2 or 10 mg/ml of LPS for 2 days in a 96-well plate. For the anti-CD40 and IL-4 culture, 50 mg/ml anti-CD40 or 20 U/ml IL-4 were included in the culture. To determine the rates of cell proliferation, cultured cells were pulsed with 
BCR Downmodulation
Purified B cells were stained with biotinylated anti-IgM (Fab')2 at 4 C for 15 min. After washing with PBS, cells were incubated at 37 C prewarmed HBSS buffer containing 1% FBS to allow internalization of BCR-anti-IgM (Fab') 2 complexes to occur. After various periods of incubation, cells were immediately transferred into cold HBSS buffer containing 0.1% sodium azide to stop further internalization. Cellsurface-remaining anti-IgM (Fab') 2 were stained with streptavidin-PE and quantified on an LSR II.
Immunoprecipitation and Immunoblot Analyses
Immunoprecipitation and immunoblot analyses were performed as previously described (Naramura et al., 2002) . In brief, purified B cells were stimulated with anti-IgM (Fab') 2 for various periods and lysed in RIPA buffer containing a mixture of proteinase and phosphatase inhibitors (0.1 mg/ml Aprotinin, 0.01 mg/ml Leupeptin, 0.2 mM PMSF, 1 mM NaF, and 1 mM NaVO 4 ). Ig-a, Syk, BLNK, Vav, and PLC-g2 in the cell lysates were immunoprecipitated with the corresponding antibodies and subjected to electrophoresis and immunoblotting. The amounts of tyrosine phosphorylation and protein ubiquitination were determined with anti-phosphotyrosine and anti-ubiquitin, respectively (Santa Cruz Biotechnology).
Histochemical and Immunofluorescent Staining
Mouse tissues were harvested, snap frozen in liquid nitrogen, and embedded in OCT-embedding medium (Sakura Finetek). 8 mM sections were air-dried and fixed with acetone. H&E staining was performed according to a standard protocol (Miyamoto et al., 2002) . Immunofluorescent staining was performed with the following reagents: anti-IgM-FITC, anti-IgG-biotin (BD Biosciences), and streptavidin-Alexa 568 (Molecular Probes). Anti-nuclear antibodies (ANA) were detected by intracellular staining of Hep2 cells with mouse serum (1:100 dilution), followed by FITC-conjugated anti-mouse IgG. Evans Blue staining was used to visualize cytoplasm.
Supplemental Data
Two figures are available at http://www.immunity.com/cgi/content/ full/26/5/567/DC1/.
